Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPRB | P23467 | 1/20 | 0.57 |
| ▸ | RNF4 | P78317 | 1/20 | 0.54 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.53 |
| ▸ | FPR2 | P25090 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | ACHE | P22303 | 1/20 | 0.47 |
| ▸ | PYGL | P06737 | 1/20 | 0.46 |
| ▸ | PPARG | P37231 | 1/20 | 0.46 |
| ▸ | PPARA | Q07869 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20427718 | 0.87 | PTPRB (0.56) | PTPRBRNF4TRPM8FPR2PPARG | |
| SCHEMBL16682060 | 0.87 | PTPRB (0.56) | PTPRBRNF4TRPM8FPR2PPARG | |
| SCHEMBL16670186 | 0.85 | FPR2 (0.53) | FPR2KMT2AALDH1A1NPC1RAB9A | |
| SCHEMBL16670359 | 0.83 | PTPRB (0.51) | PTPRBRNF4TRPM8FPR2KMT2A | |
| SCHEMBL16670358 | 0.83 | PTPRB (0.51) | PTPRBRNF4TRPM8FPR2KMT2A | |
| SCHEMBL16682042 | 0.81 | RNF4 (0.57) | RNF4TRPM8KMT2AALDH1A1LMNA | |
| SCHEMBL16669947 | 0.81 | RNF4 (0.57) | RNF4TRPM8KMT2AALDH1A1LMNA | |
| SCHEMBL16682162 | 0.81 | FPR2 (0.54) | PTPRBTRPM8FPR2KMT2AALDH1A1 | |
| SCHEMBL16670145 | 0.79 | PTPRB (0.47) | PTPRBRNF4TRPM8FPR2KMT2A | |
| SCHEMBL16670144 | 0.79 | PTPRB (0.47) | PTPRBRNF4TRPM8FPR2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10035760-B2 | Inhibitors of human immunodeficiency virus replication | VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) | 2018-07-31 | — | — | US | disclosed |
| US-20160257645-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV Healthcare UK (No.5) Limited (GB) | 2016-09-08 | — | — | US | disclosed |
| EP-3060554-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | Bristol-Myers Squibb Company (US) | 2016-08-31 | — | — | EP | disclosed |
| WO-2015061518-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-04-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160257645-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | EIF2AK2, POLR1E, POLR1G | PTPRB 3674/4885RNF4 1646/4885TRPM8 4660/4885 |
| US-10035760-B2 | Inhibitors of human immunodeficiency virus replication | EIF2AK2, POLR1G, POLR1E | PTPRB 3692/4885RNF4 1773/4885TRPM8 4685/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.